Mitochondrially targeted tamoxifen as anticancer therapy: case series of patients with renal cell carcinoma treated in a phase I/Ib clinical trial

Loading...
Thumbnail Image
File version

Version of Record (VoR)

Author(s)
Bielcikova, Zuzana
Werner, Lukas
Stursa, Jan
Cerny, Vladimir
Krizova, Ludmila
Spacek, Jan
Hlousek, Stanislav
Vocka, Michal
Bartosova, Olga
Pesta, Michal
Kolostova, Katarina
Klezl, Petr
Bobek, Vladimir
Truksa, Jaroslav
Stemberkova-Hubackova, Sona
et al.
Griffith University Author(s)
Primary Supervisor
Other Supervisors
Editor(s)
Date
2023
Size
File type(s)
Location
Abstract

Mitochondrially targeted anticancer drugs (mitocans) that disrupt the energy-producing systems of cancer are emerging as new potential therapeutics. Mitochondrially targeted tamoxifen (MitoTam), an inhibitor of mitochondrial respiration respiratory complex I, is a first-in-class mitocan that was tested in the phase I/Ib MitoTam-01 trial of patients with metastatic cancer. MitoTam exhibited a manageable safety profile and efficacy; among 37% (14/38) of responders, the efficacy was greatest in patients with metastatic renal cell carcinoma (RCC) with a clinical benefit rate of 83% (5/6) of patients. This can be explained by the preferential accumulation of MitoTam in the kidney tissue in preclinical studies. Here we report the mechanism of action and safety profile of MitoTam in a case series of RCC patients. All six patients were males with a median age of 69 years, who had previously received at least three lines of palliative systemic therapy and suffered progressive disease before starting MitoTam. We recorded stable disease in four, partial response in one, and progressive disease (PD) in one patient. The histological subtype matched clear cell RCC (ccRCC) in the five responders and claro-cellular carcinoma with sarcomatoid features in the non-responder. The number of circulating tumor cells (CTCs) was evaluated longitudinally to monitor disease dynamics. Beside the decreased number of CTCs after MitoTam administration, we observed a significant decrease of the mitochondrial network mass in enriched CTCs. Two patients had long-term clinical responses to MitoTam, of 50 and 36 weeks. Both patients discontinued treatment due to adverse events, not PD. Two patients who completed the trial in November 2019 and May 2020 are still alive without subsequent anticancer therapy. The toxicity of MitoTam increased with the dosage but was manageable. The efficacy of MitoTam in pretreated ccRCC patients is linked to the novel mechanism of action of this first-in-class mitochondrially targeted drug.

Journal Title

Therapeutic Advances in Medical Oncology

Conference Title
Book Title
Edition
Volume

15

Issue
Thesis Type
Degree Program
School
Publisher link
Patent number
Funder(s)
Grant identifier(s)
Rights Statement
Rights Statement

© The Author(s), 2023. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).

Item Access Status
Note
Access the data
Related item(s)
Subject

Oncology and carcinogenesis

Science & Technology

Life Sciences & Biomedicine

Oncology

case series

efficacy

Persistent link to this record
Citation

Bielcikova, Z; Werner, L; Stursa, J; Cerny, V; Krizova, L; Spacek, J; Hlousek, S; Vocka, M; Bartosova, O; Pesta, M; Kolostova, K; Klezl, P; Bobek, V; Truksa, J; Stemberkova-Hubackova, S; Petruzelka, L; Michalek, P; Neuzil, J, Mitochondrially targeted tamoxifen as anticancer therapy: case series of patients with renal cell carcinoma treated in a phase I/Ib clinical trial, Therapeutic Advances in Medical Oncology, 2023, 15

Collections